- Home
- IPXX vs TRVI Comparison
IPXX vs TRVI Comparison
Compare IPXX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPXX
- TRVI
- Stock Information
- Founded
- IPXX 2023
- TRVI 2011
- Country
- IPXX United States
- TRVI United States
- Employees
- IPXX N/A
- TRVI N/A
- Industry
- IPXX Blank Checks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- IPXX Finance
- TRVI Health Care
- Exchange
- IPXX Nasdaq
- TRVI Nasdaq
- Market Cap
- IPXX 386.5M
- TRVI 341.4M
- IPO Year
- IPXX 2023
- TRVI 2019
- Fundamental
- Price
- IPXX $13.05
- TRVI $3.56
- Analyst Decision
- IPXX
- TRVI Strong Buy
- Analyst Count
- IPXX 0
- TRVI 8
- Target Price
- IPXX N/A
- TRVI $9.31
- AVG Volume (30 Days)
- IPXX 5.8K
- TRVI 659.4K
- Earning Date
- IPXX 01-01-0001
- TRVI 03-19-2025
- Dividend Yield
- IPXX N/A
- TRVI N/A
- EPS Growth
- IPXX N/A
- TRVI N/A
- EPS
- IPXX 0.37
- TRVI N/A
- Revenue
- IPXX N/A
- TRVI N/A
- Revenue This Year
- IPXX N/A
- TRVI N/A
- Revenue Next Year
- IPXX N/A
- TRVI N/A
- P/E Ratio
- IPXX $34.92
- TRVI N/A
- Revenue Growth
- IPXX N/A
- TRVI N/A
- 52 Week Low
- IPXX $10.37
- TRVI $1.30
- 52 Week High
- IPXX $15.18
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- IPXX 61.12
- TRVI 43.13
- Support Level
- IPXX $12.30
- TRVI $3.63
- Resistance Level
- IPXX $13.18
- TRVI $4.06
- Average True Range (ATR)
- IPXX 0.69
- TRVI 0.30
- MACD
- IPXX 0.06
- TRVI -0.11
- Stochastic Oscillator
- IPXX 69.85
- TRVI 0.44
About IPXX Inflection Point Acquisition Corp. II
Inflection Point Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.